Daiichi Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Tokyo Japan (1915)
Status: Acquired by Daiichi Sankyo (2005)

Organization Overview

First Clinical Trial
1999
NCT00005091
First Marketed Drug
1997
ofloxacin (floxin)
First NDA Approval
None
Last Known Activity
2004

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

DAIICHI | Daiichi Pharmaceuticals

Active Ingredients

Marketed Drugs (1)

ofloxacin (floxin) (1997)

Drugs in Phase 3 Trials (1)

clopidogrel (plavix) (1 trial)

Drugs in Phase 2 Trials (3)

exatecan (1 trial)

soblidotin (2 trials)

tesetaxel (1 trial)

Drugs in Phase 1 Trials (2)

gemcitabine (gemzar) (1 trial)

tecogalan (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Coronary Syndrome (Phase 3)

Adenocarcinoma (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Lung Neoplasms (Phase 2)

Neoplasms (Phase 1)

Sarcoma (Phase 1)

Sarcoma, Kaposi (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial APIs: 6